About this condition
Gaucher Disease
Gaucher disease is an autosomal recessive lysosomal storage disorder caused by GBA mutations, which encode glucocerebrosidase — the enzyme that breaks down glucocerebroside into glucose and ceramide. Loss-of-function GBA variants impair this breakdown, causing glucocerebroside to accumulate in macrophages and other cells, creating characteristic lipid-laden Gaucher cells. The disease manifests in three clinical types: Type 1 (non-neuronopathic, ~95% of cases) features hepatosplenomegaly, anemia, thrombocytopenia, and progressive bone disease; Type 2 (acute neuronopathic, rare) is fatal by age 2–4; and Type 3 (chronic neuronopathic) shows progressive neurological decline alongside organ involvement.
Gaucher disease affects approximately 1 in 40,000 to 1 in 60,000 individuals globally, though prevalence is dramatically higher in Ashkenazi Jewish populations (~1 in 850). Over 400 GBA variants have been identified. Four Ashkenazi founder mutations — N370S, 84GG, L444P, and IVS2+1G>A — account for approximately 96% of alleles in that population. Genotype predicts severity: Type 1 (non-neuronopathic) variants typically retain residual enzyme activity (~10–30%), while Type 2/3 (neuronopathic) variants reduce activity more profoundly or produce misfolded enzyme. Interestingly, heterozygous GBA carriers (approximately 1–3% of the general population) have a 5–10-fold increased risk of Parkinson's disease, revealing an unexpected link between lysosomal dysfunction and neurodegeneration.
A confirmed GBA pathogenic variant diagnosis enables enzyme replacement therapy (imiglucerase, velaglucerase alfa) or substrate reduction therapy (eliglustat for Type 1, miglustat for Types 1 and 3) — both FDA-approved and directly targeting the molecular consequence of GBA loss. Type 1 (non-neuronopathic) variants typically respond well, with therapies reducing hepatosplenomegaly, improving hematologic parameters, and halting bone disease progression. Type 2 (acute neuronopathic) does not currently have effective disease-modifying treatments. Type 3 shows variable response to enzyme replacement. Treatment efficacy correlates with genotype: N370S (milder) typically responds better than L444P (more severe). Genetic diagnosis enables early treatment initiation, preventing irreversible organ and bone complications.
GBA genotype predicts clinical type and treatment response — Type 1 variants typically respond well to enzyme replacement or substrate reduction therapy, while Type 2 remains untreatable and Type 3 shows variable response.
- Gene locus
- GBA (1q22)
